VirtualScopics and IXICO Alliance Receive Awards in Oncology and Neurodegenerative Disease

ROCHESTER, N.Y., June 29, 2015 /PRNewswire/ -- VirtualScopics, Inc. VSCP, a leading provider of clinical trial imaging solutions, along with IXICO plc IXI, the brain health company, announced today the alliance has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumors and one in a rare neurodegenerative disease. IXICO's TrialTracker™ digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO's Assessa® digital technology will be used to analyze MRI data collected from patients.

The metastatic solid tumor study will make use of VirtualScopics extensive expertise applying FDG-PET (Fludeoxyglucose PET) to measuring disease progression in oncology and will involve working with imaging centers across North America and Europe. The study is expected to complete in June 2017.

The neurodegeneration study will make use of IXICO's expertise in structural MRI and will involve IXICO working with key opinion leaders across specialist imaging centers throughout North America. As part of this contract, IXICO's Assessa® medical device will utilize its proprietary LEAP methodology to quantify disease pathology in brain regions that are particularly relevant to measuring disease progression and will be applied to MRI data collected from subjects enrolled in the study. The study is expected to complete in January 2018.

Eric Converse, Chief Executive Officer of VirtualScopics commented: "Winning these two recent studies with IXICO clearly demonstrates the strength of our alliance. We are bringing a viable, stronger imaging choice to the risk-averse pharmaceutical industry. The list of studies on TrialTracker™ within VirtualScopics continues to grow with increased momentum. Customers are very pleased with this option. TrialTracker™ is the backbone of our relationship with IXICO and allows us to fully exploit our collaborative offering."

Professor Derek Hill, Chief Executive Officer of IXICO, commented: "Our alliance with VirtualScopics continues to be valued by our pharmaceutical partners as we support their clinical trials on a global basis, as evidenced by these two new contract wins. Our TrialTracker™ digital platform provides customers with digital technology combined with operational effectiveness.  Furthermore, our involvement with the neurodegenerative disease study demonstrates our ability to broaden our therapeutic expertise and validates the importance of IXICO's technology across a range of brain diseases."

About VirtualScopics, Inc.
VirtualScopics, Inc. VSCP is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development. For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly-accepted services provided by other clinical trial imaging providers. Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, everyday clinical trial imaging services. For more information on VirtualScopics, Inc. please visit www.virtualscopics.com.

About IXICO plc
IXICO plc, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid decisions and improve patient outcomes. Established since 2004, IXICO has significant experience in working with global pharmaceutical and biotechnology companies in dementia clinical studies and other neuro-degenerative disorders including Huntington's disease and Multiple Sclerosis.  More information is available on www.ixico.com.

Forward-looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the company's investment in infrastructure, sales and marketing efforts, the increase in backlog, awards and bookings and the performance of existing projects and/or statements preceded by, followed by or that include the words "believes", "could", "expects", "anticipates", "estimates", "intends", "plans", "projects", "seeks", or similar expressions.  Forward-looking statements deal with the company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or that contract awards do not turn into signed contracts. Other risks include the company's dependence on its largest customers and risk of contract performance, protection of our intellectual property and the risks of infringement on the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to update such forward-looking statements.

For More Information, Contact:
Donna N. Stein, APR, Fellow PRSA
Managing Partner
Donna Stein & Partners
315-361-4672
Email:  dstein1@twcny.rr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/virtualscopics-and-ixico-alliance-receive-awards-in-oncology-and-neurodegenerative-disease-300105797.html

SOURCE VirtualScopics, Inc.